This statistic reveals the revenues generated by top product Revlimid from 2008 to 2024. In 2024, one of the leading cancer drugs globally generated revenues of about 5.8 billion U.S. dollars. Revenues dropped dramatically since the launch of a generic version of the drug in March 2022. Revlimid was developed by Celgene Corporation, a former company headquartered in Summit, New Jersey. The company was specialized in drug manufacturing for cancer and inflammatory disorders. During 2019, the company was acquired by Bristol Myers Squibb.
Revenue of top product Revlimid from 2008 to 2024
(in million U.S. dollars)
The statistic was assembled from several annual reports.
* Transition year (BMS' acquisition of Celgene); value is rounded.
** Year of first generic version on the market.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Bristol-Myers Squibb, & U.S. Securities and Exchange Commission. (February 12, 2025). Revenue of top product Revlimid from 2008 to 2024 (in million U.S. dollars) [Graph]. In Statista. Retrieved February 15, 2025, from https://www.statista.com/statistics/1269411/revenues-of-revlimid/?__sso_cookie_checker=failed
Bristol-Myers Squibb, und U.S. Securities and Exchange Commission. "Revenue of top product Revlimid from 2008 to 2024 (in million U.S. dollars)." Chart. February 12, 2025. Statista. Accessed February 15, 2025. https://www.statista.com/statistics/1269411/revenues-of-revlimid/?__sso_cookie_checker=failed
Bristol-Myers Squibb, U.S. Securities and Exchange Commission. (2025). Revenue of top product Revlimid from 2008 to 2024 (in million U.S. dollars). Statista. Statista Inc.. Accessed: February 15, 2025. https://www.statista.com/statistics/1269411/revenues-of-revlimid/?__sso_cookie_checker=failed
Bristol-Myers Squibb, and U.S. Securities and Exchange Commission. "Revenue of Top Product Revlimid from 2008 to 2024 (in Million U.S. Dollars)." Statista, Statista Inc., 12 Feb 2025, https://www.statista.com/statistics/1269411/revenues-of-revlimid/?__sso_cookie_checker=failed
Bristol-Myers Squibb & U.S. Securities and Exchange Commission, Revenue of top product Revlimid from 2008 to 2024 (in million U.S. dollars) Statista, https://www.statista.com/statistics/1269411/revenues-of-revlimid/?__sso_cookie_checker=failed (last visited February 15, 2025)
Revenue of top product Revlimid from 2008 to 2024 (in million U.S. dollars) [Graph], Bristol-Myers Squibb, & U.S. Securities and Exchange Commission, February 12, 2025. [Online]. Available: https://www.statista.com/statistics/1269411/revenues-of-revlimid/?__sso_cookie_checker=failed
